ADCs in Oncology: When Clinical Promise Moves Faster Than Practice Confidence

A therapy can look highly promising in a trial and still feel conditional at the bedside. 

That is where antibody-drug conjugates now sit in oncology practice. ADCs have moved from specialist enthusiasm into real treatment conversations across solid tumors. Their design is compelling: an antibody directs a cytotoxic payload toward tumor cells expressing a specific target, aiming to combine precision with potency. In principle, that should make ADCs feel like a cleaner evolution of systemic therapy. 

In practice, oncologists are describing something more nuanced. 

Like car T cell therapy, ADCs represent a major step toward precision oncology, but their real-world success depends not only on clinical efficacy, but also on patient selection, toxicity management, and thoughtful treatment sequencing.

The current question is no longer whether ADCs matter. They clearly do. The harder question is how confidently they can be selected, sequenced, and managed when patients no longer resemble trial populations. 

An MDForLives pulse survey among oncologists across major markets in North America and Western Europe shows this clearly. ADCs are advancing, but practice confidence is not advancing at the same speed.

ADCs Are Important, but Still Selective

In the MDForLives findings, 53.1% of oncologists described ADCs as “highly promising but still selective.” Only 20.3% called them transformational, while 21.9% saw them as offering incremental benefit in specific settings. 

That distribution is important. It does not suggest weak clinical interest. It suggests disciplined confidence. 

Oncologists are not dismissing ADCs. They are placing boundaries around where the class feels strongest and where real-world uncertainty still matters. This is especially relevant as ADCs expand beyond established indications and into broader solid tumor use. 

The insight is not that ADCs are underperforming. It is that oncologists are resisting the temptation to treat the class as uniformly transformative. In real practice, the question is not “Do ADCs work?” It is “Which ADC, in which patient, at which point in the pathway, and with what toxicity readiness?”

Breast Cancer Leads, but Multi-Tumor Thinking Is Growing 

Breast cancer remains the clearest anchor of perceived near-term ADC impact, cited by 37.5% of respondents. But almost as many oncologists, 35.9%, pointed to multiple tumor types. 

That near tie tells a bigger story. 

ADCs are no longer being viewed only through the lens of one disease area. They are increasingly being understood as a platform approach that may influence treatment thinking across breast, lung, gastrointestinal, gynecologic, and other solid tumor settings. 

As research continues to reshape care across solid tumors, advances in Osteosarcoma Treatment also highlight how targeted therapies and evolving treatment strategies are expanding options for patients with complex cancers.

But platform expansion is not only a scientific development. It is an operational one. 

If ADC use spreads across tumor types, clinics need consistent testing pathways, biomarker interpretation, toxicity monitoring, imaging cadence, dose-adjustment protocols, and multidisciplinary coordination. A therapy that expands across disease teams can create a new layer of shared oncology workflow. 

That is why ADC growth may depend as much on service readiness as on clinical enthusiasm.

Trial Efficacy Starts the Conversation 

When oncologists were asked what most influences the decision to initiate an ADC, 60.9% selected strength of trial efficacy data. Target expression and patient selection came next at 23.4%. 

This finding makes sense. In a fast-moving oncology landscape, trial results still provide the strongest justification for introducing a therapy into routine care. Oncologists need evidence that the treatment changes outcomes meaningfully before accepting the complexity that follows. 

But the gap between trial efficacy and patient selection is also revealing. 

The decision to start may be evidence-led. The work after starting is often toxicity-led, adjustment-led, and pathway-led. That means the confidence needed to begin therapy is different from the confidence needed to sustain it. 

This is where real-world oncology becomes more complex than protocol logic. Patients arrive with prior treatment exposure, comorbidities, organ function variability, frailty concerns, and competing treatment options. Trial data may open the door, but patient selection decides how carefully clinicians walk through it.

Selection Confidence Remains Moderate, Not Absolute 

The MDForLives survey shows that 57.8% of oncologists report only moderate confidence selecting patients for ADC therapy outside trials. A smaller but meaningful 34.4% describe themselves as very confident. 

Moderate confidence should not be misread as hesitation. In this context, it may be closer to clinical vigilance. 

ADCs require oncologists to balance efficacy expectations against patient-specific vulnerability. The same therapy may feel appropriate in one patient and risky in another, even within the same tumor type. This is particularly true when target expression, prior line exposure, pulmonary risk, and tolerability history all influence the decision. 

The core implication is that ADC adoption cannot scale through approvals alone. It also needs sharper selection frameworks, more real-world evidence, and clinician experience across patient groups that trials may not fully represent.

Similar implementation challenges have been observed with GLP-1 Therapy in Obesity Care, where expanding clinical adoption has highlighted the importance of patient selection, long-term management, and translating trial evidence into routine practice.

ILD Is More Than a Toxicity Signal 

Among toxicity concerns, interstitial lung disease stands out clearly. In the survey, 45.3% of oncologists identified ILD as the leading concern limiting ADC use. 

That number matters because ILD is not just another adverse event category. It changes how clinicians think about surveillance, early symptom recognition, imaging, dose interruption, steroid use, multidisciplinary referral, and patient counselling. 

Patient counselling should also include discussions about complementary therapies and dietary supplements, making it important to understand the Safety of Ashwagandha and other products that patients may use alongside cancer treatment.

In the same survey, 60.9% said ADC toxicities are manageable, but only with frequent adjustments. This pairing is the heart of the real-world friction. 

Oncologists are not saying toxicity makes ADCs unusable. They are saying toxicity makes ADCs resource-demanding. The challenge is not only whether adverse events can be managed. It is how often the care team must intervene, adjust, monitor, and reassess to keep treatment safe and meaningful. 

Supportive care strategies, including Pain Management, can play an important role in helping patients cope with treatment-related symptoms, improve quality of life, and remain on therapy when clinically appropriate.

That is why ILD becomes a workflow issue as much as a safety issue. 

Sequencing Is Still Settling 

Today, 53.1% of respondents place ADCs most commonly in mid-line settings after standard options. This reflects a pragmatic balance: ADCs are seen as strong enough to move beyond late refractory use, but not yet routine enough to dominate earlier treatment lines across settings. 

Sequencing uncertainty is one of the most important unresolved questions for the next phase of ADC adoption. 

Should an ADC move earlier if trial efficacy is strong? Should it be held until after standard options? How should clinicians sequence ADCs against immunotherapy, targeted therapy, chemotherapy, or another ADC with overlapping payload risks? What does prior exposure mean for resistance, tolerability, or later-line benefit? 

These are not abstract questions. They affect real patients at real decision points. 

As ADCs expand, sequencing will become less about where the therapy is approved and more about where it creates the strongest net value across the full patient pathway.

Expansion Is Expected, but Not Unconditional 

Despite the friction, oncologists expect ADC use to grow. In the MDForLives survey, 62.5% anticipate significant expansion over the next two to three years. 

At the same time, confidence in emerging trial readouts remains split. While 45.3% describe upcoming evidence as practice-changing, 40.6% see it as informative but not decisive. 

That split is important. It shows that oncologists are watching the evidence closely, but not assuming that every positive signal will immediately transform routine care. 

The next phase of ADC adoption will likely be selective, indication-specific, and workflow-dependent. It will move fastest where patient selection is clearer, toxicity monitoring is mature, reimbursement is workable, and sequencing logic is defensible.

Closing Perspective 

ADCs are one of the most clinically important oncology advances in recent years. They bring targeted delivery, strong trial momentum, and growing relevance across solid tumors. 

But the MDForLives findings show that real-world adoption is shaped by more than efficacy. 

Most oncologists see ADCs as highly promising but still selective. Selection confidence outside trials remains moderate. ILD is the leading toxicity concern. Toxicities are manageable, but often only with frequent adjustments. Sequencing is moving forward, but not yet settled. 

This is not a negative signal for ADCs. It is a realistic picture of what happens when a powerful therapy class begins to scale across complex oncology pathways. 

ADCs are advancing quickly. The next challenge is making sure confidence, infrastructure, and clinical judgment can keep pace.

FAQs 

What are antibody-drug conjugates in oncology? 

Antibody-drug conjugates, or ADCs, are targeted cancer therapies that link a monoclonal antibody to a cytotoxic payload. The antibody helps direct the payload toward cancer cells expressing a specific target. 

Are ADCs considered transformational in solid tumors?

In the MDForLives pulse, only 20.3% of oncologists described ADCs as transformational. The largest group, 53.1%, called them highly promising but still selective.

What most influences ADC initiation in real-world practice?

Trial efficacy data is the strongest initiation driver, selected by 60.9% of oncologists, followed by target expression and patient selection at 23.4%.

What is the leading toxicity concern with ADCs?

Interstitial lung disease is the leading toxicity concern in the MDForLives findings, cited by 45.3% of oncologists.

Are ADC toxicities manageable in routine oncology care?

Most oncologists in the survey describe ADC toxicities as manageable, but 60.9% say they require frequent adjustments, suggesting a meaningful care-pathway burden.

Where do ADCs most commonly fit in treatment sequencing today?

ADCs are most commonly positioned in mid-line settings after standard options, according to 53.1% of respondents.